DAEWOONG PHARMA
Financials
Valuation Metrics
DAEWOONG PHARMA's Market Cap is ₩1.2T. At end of 2025 it was ₩2.0T. Ranked #272 of 2,414 in KR market (top 11%), #204 of 781 on KOSPI (top 26%), #29 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 13%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.22T KRW | KR#272/2,414 Sec#29/231 |
| Revenue | 1.64T KRW | KR#297/2,414 Sec#10/231 |
| Net Income | 178.44B KRW | KR#167/2,414 Sec#9/231 |
| Total Assets | 2.54T KRW | KR#265/2,414 Sec#9/231 |
| Net Assets | 1.19T KRW | KR#257/2,414 Sec#13/231 |
| Employees | 1,757 | KR#157/2,414 Sec#7/231 |
| Value | ||
| P/E | 6.84x | KR#601/2,414 Sec#25/231 |
| P/B | 1.02x | KR#1,534/2,414 Sec#96/231 |
| PEG | 0.02x | KR#177/2,414 Sec#6/231 |
| P/S | 0.75x | KR#1,229/2,414 Sec#65/231 |
| EV/EBITDA | 12.05x | KR#753/2,414 Sec#41/231 |
| FCF Yield | -3.47% | KR—/2,414 Sec—/231 |
| Profitability | ||
| ROE | 14.98% | KR#327/2,414 Sec#22/231 |
| ROA | 7.03% | KR#513/2,414 Sec#40/231 |
| Op. Margin | 11.65% | KR#435/2,414 Sec#39/231 |
| Revenue Growth | 9.87% | KR#906/2,414 Sec#88/231 |
| Earnings Growth | 372.29% | KR#135/2,414 Sec#8/231 |
| Financial Health | ||
| Debt Ratio | 112.98% | KR#1,650/2,414 Sec#187/231 |
| Total Debt | 1.23T KRW | KR#182/2,414 Sec#5/231 |
| FCF | -42.33B KRW | KR#2,050/2,414 Sec#203/231 |
| Cash | 154.74B KRW | KR#332/2,414 Sec#14/231 |
| Current Ratio | 0.89x | KR#1,850/2,414 Sec#180/231 |
| Net Debt/EBITDA | 5.65x | KR#1,069/2,414 Sec#79/231 |
| Dividend | ||
| Div. Yield | 0.57% | KR#1,257/2,414 Sec#78/231 |
| Div. Growth | 0.00% | KR—/2,414 Sec—/231 |
| Performance | ||
| 1Y Return | -21.94% | KR#1,231/2,414 Sec#88/231 |
| 1M Return | -4.19% | KR#911/2,414 Sec#82/231 |
| From 52W High | -47.19% | KR#1,090/2,414 Sec#84/231 |
| 1Y MDD | -46.60% | KR#830/2,414 Sec#66/231 |
| Trading | ||
| Volume | 22,092 shares | KR#1,783/2,414 Sec#175/231 |
| Trading Value | 2.31B KRW | KR#551/2,414 Sec#57/231 |
| Foreign Own. | 14.87% | KR#323/2,414 Sec#20/231 |
| Per Share | ||
| EPS | 15,401 KRW | KR#69/2,414 Sec#4/231 |
| BPS | 102,833 KRW | KR#129/2,414 Sec#7/231 |
Company Info
Daewoong Pharmaceutical was established in 2002 as a spin-off from Daewoong Co., Ltd., focusing on pharmaceutical manufacturing and sales. The company operates KGMP-compliant facilities in Hyangnam Industrial Complex, Hwaseong-si, and Osong Bio-Science Complex, Cheongju-si, producing key products like Nabota, Ursa, and Fexuclue. It is advancing global expansion with three innovative new drugs—Fexuclue, Envlo, and Nabota—pursuing a '1 Product, 1 Trillion Won' vision, and growing through digital healthcare investments and new drug development. It is headquartered in Hwaseong-si, Gyeonggi-do.